The incidence of counterfeit life sciences products has increased in recent years. With the expansion of illicit online pharmacies and the rise in unauthorized compounded medications, this trend is expected to persist and potentially worsen.
Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the US and the EU.
The selling of counterfeit life sciences products endangers patients’ lives and violates contract provisions that cause harm to manufacturers. As litigation surrounding counterfeit pharmaceuticals and medical devices increases, manufacturers seek compensation for the harm realized.
CRA’s Erin McDermott and Taylor Rubinato explore the different types of counterfeit products encountered by manufacturers and the harms for which manufacturers can be compensated.
Read more about the consequences of counterfeit pharmaceutical product sales here.
